Aptiv Solutions Announces Launch of a Unique Global Biopharmaceutical and Medical Device Development Services Company …
Chairman and CEO Patrick K. Donnelly today announced the launch of Aptiv Solutions, a global biopharmaceutical and medical device development services company focused on recognizing, understanding and enabling clients to capitalize on rapid and fundamental changes facing companies developing products in the pharmaceutical, biotech and medical device market.
This video outlines the opportunities available to Irish researchers, SMEs and multi-national corporations for R&D funding through the Seventh Framework Programme. This programme runs until 2013. If you wish to find out further information on FP7, contact: Dr. Imelda Lambkin Enterprise Ireland +353 (0)1 727 2665 or imelda.lambkin@enterprise-ireland.com www.fp7ireland.com Ireland has already benefitted greatly from previous EU Framework programmes, with our third level and company-based researchers drawing down almost €200 million from the Sixth EU Framework Programme. The Seventh EU Framework Programme for Research and Technological Development (FP7) was launched at the end of 2006 with a budget of approximately €50 billion covering the period 2007 to 2013. Under the Strategy for Science, Technology and Innovation (SSTI) 2006-2013, Ireland has set a goal to become a leader in research and development and innovation. The SSTI sets a target of €400 million to be secured by Irish participants in FP7. This target was set, however, before the final structure and budgets for FP7 had been finalised. Over recent months, work has taken place to establish a set of indicators by which Irish participation in FP7 would be monitored and to propose a new, more detailed set of targets for Irish participation in the programme up to the end of 2013. Based on the work undertaken, the Cabinet Committee has agreed that the total share of EU funding to be targeted by Ireland over the lifetime …
Actelion, Glaxo Stop Development of Insomnia Medicine on Safety Concern
Actelion Ltd. and partner GlaxoSmithKline Plc stopped late-stage development of the experimental almorexant insomnia pill because of concern that patients wouldn’t be able to tolerate the medicine.
PolyMedix Promotes Bozena Korczak to Senior Vice President, Drug Development and Chief Development Officer
PolyMedix, Inc. , an emerging biotechnology company focused on developing new therapeutic drugs for the treatment of serious infectious diseases and acute cardiovascular disorders, announces the promotion of Bozena Korczak, Ph.D. to Senior Vice President, Drug Development and Chief Development Officer.
Saratoga County, New York (USA) 518-587-0945 or www.saratogaedc.com World-changing innovations – Visionary leaders Highly-skilled workforce. What do these have in common? They have always had a home in Saratoga County, New York. Saratoga County offers proximity to major markets, superior infrastructure, access to capital and is now home to GLOBALFOUNDRIES Fab 8. From research to design commercialization to manufacturing , you will find all the tools and resources you need to succeed. Saratoga County has an environment designed for growth. Semiconductors, Clean tech, Nanotech, Biotech – the businesses located here are already changing the future. Saratoga County has abundant natural resources and year-round beauty. This is a place where your employees will feel a special sense of home. Once theyre in Saratoga County, theyll never want to leave. Saratoga County offers a vibrant, thriving community, Diverse and friendly neighborhoods. Award-winning schools and healthcare. Come discover Saratoga County. It’s life with balance and it’s your new home.
Dr. B.Lal Biotechnology College in Jaipur offers Biotechnology Research & Development, Clinical Research, Paramedical courses, B.Sc. Biotechnology, B.Sc. Biotechnology, M.Sc. Biotechnology, M.Sc. Clinical Microbiology, Pharma biotechnology and Biotech summer and industrial training program in Jaipur
UBC Innovation Is Advanced By The Centre For Drug Research And Development And Licensed By Global Healthcare Company
The University of British Columbia (UBC) and the Centre for Drug Research and Development (CDRD) recently announced that Covidien, a leading global provider of healthcare products, has licensed an innovative drug-delivery platform technology invented by UBC researcher, Pieter Cullis
